Vonlerolizumab
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134) . Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models[1].
Product Specifications
CAS Number
[1638935-72-4]
Product Name Alternative
Pogalizumab; MOXR 0916
UNSPSC
12352203
Target
Orexin Receptor (OX Receptor)
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vonlerolizumab.html
Purity
99.70
Solubility
10 mM in DMSO
Smiles
[Vonlerolizumab]
Molecular Weight
(145.26 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BLNK, NT (BLNK, BASH, SLP65, B Cell linker protein, B Cell adapter containing a SH2 domain protein, B Cell adapter containing a Src homology 2 domain protein, Cytoplasmic adapter protein, Src homology 2 domain-containing leukocyte protein of 65kD) (FITC)
BLNK, NT (BLNK, BASH, SLP65, B Cell linker protein, B Cell adapter containing a SH2 domain protein, B Cell adapter containing a Src homology 2 domain protein, Cytoplasmic adapter protein, Src homology 2 domain-containing leukocyte protein of 65kD) (FITC)
